CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 474 target
Drug / intervention
Chemotherapy +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05780372
NCT05780372Phase 3ActiveUpdate OverdueCompletion was 15mo ago
Enrollment Stalled

Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma: a Multi-center, Non-inferiority, Open-label, Randomized Controlled Phase III Clinical Trial

Sun Yat-sen University·interventional·Posted Mar 22, 2023·Updated May 11, 2026

In Brief

A Phase 3 clinical trial evaluating Intensity Modulated Radiation Therapy and Chemotherapy for Nasopharyngeal Carcinoma and Radiotherapy; Complications. Active but no longer recruiting, targeting 474 participants across 7 sites.

Signals

Enrollment appears stalled

Detailed Summary

This is a multi-center, non-inferiority, open-label, randomized controlled phase III clinical trial in primary diagnosed nasopharyngeal carcinoma (NPC) patients without distant metastasis. The purpose of this study is to evaluate the efficacy of reduced neck prophylactic radiotherapy versus conventional neck prophylactic radiotherapy, and compare the radiotherapy-related adverse events and quality of life in two groups.

Study Details

Timeline

Phase 3Active
20242025202620272028
First PostedMar 22, 2023
Enrollment StartAug 8, 2023
Primary CompletionApr 1, 2025
Study CompletionApr 1, 2028
TodayJul 1, 2026
Enrollment to primary: 1.6 yearsPosted 3.3 years ago

Interventions

Intensity Modulated Radiation Therapyradiation

All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node),60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions. The details of dose limits for organs at risk are based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).

Chemotherapydrug

Chemotherapy will be arranged by the physician-in-charge according to the NCCN guideline, patient's stage and physical condition.